A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

• Status: Terminated
• Trial end date: 2020-10-30
• Target enrollment: 0
• Participant gender: All

Summary

The reason for this study is to see if the study drug LY3499446 is safe and effective in participants with solid tumors with KRAS G12C mutation.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Cetuximab; Docetaxel; Erlotinib Hydrochloride

Criteria

Inclusion Criteria:

• Participants must have diagnosis of a solid tumor with KRAS G12C mutation that did not respond to at least 1 line of standard therapy and has spread to other part(s) of the body

• For phase II, participants must be willing to have new tumor tissue biopsies (doctor removes a small amount of tissue) during the study if it does not cause undue risks to health

• Participants must be willing to use highly effective birth control

• Participants must have adequate organ function

• Participants must be able to swallow capsules

Exclusion Criteria:

• Participants must not have certain infections such as hepatitis or tuberculosis or HIV that is not well controlled

• Participants must not have another serious medical condition including a serious heart condition, such as congestive heart failure, unstable angina pectoris, or heart attack within the last three months

• Participants must not have cancer of the central nervous system that is not stable

• Participants must not be pregnant or breastfeeding

• Participants must not use herbal supplements